Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir and Tocilizumab in severe COVID-19
NCT04678739Phase 3Completed
- Sponsor
- M Abdur Rahim Medical College and Hospital
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of remdesivir and tocilizumab in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by M Abdur Rahim Medical College and Hospital. Primary endpoint: Time to Clinical Improvement at 30 days. Started Aug 2020; status: completed.
02
Drugs
remdesivirtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04678739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678739.